Cargando…
Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885922/ https://www.ncbi.nlm.nih.gov/pubmed/36715832 http://dx.doi.org/10.1007/s10238-023-00999-1 |
_version_ | 1784880027996782592 |
---|---|
author | Chen, Ruxuan Shao, Chi Liu, Xiangning Huang, Hui Pan, Boju Xu, Kai Zhu, Rui Li, Mei Zhao, Yang Chen, Keqi Wang, Mengzhao Xu, Zuojun |
author_facet | Chen, Ruxuan Shao, Chi Liu, Xiangning Huang, Hui Pan, Boju Xu, Kai Zhu, Rui Li, Mei Zhao, Yang Chen, Keqi Wang, Mengzhao Xu, Zuojun |
author_sort | Chen, Ruxuan |
collection | PubMed |
description | This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective analysis of the clinical characteristics of hospitalized LC patients with definite pathological diagnoses was performed from 2014 to 2021. ILD was defined after the review of chest CT imaging. There were 13,085 hospitalized LC patients. Among them, 509 patients (3.89%) had 551 cases of ILD. There were variable underlying causes of ILD, including idiopathic interstitial pneumonia (360 patients), LC treatment-associated ILD (134 cases), and connective tissue disease-associated ILD (55 patients). Although most LC-ILD patients were suffering from adenocarcinoma (204/40.1%), SCLC patients were prone to concomitant ILD (10.8% of all SCLC cases), followed by SCC (9.6% of all SCC cases). All but 10 LC-ILD patients received anti-LC treatment; however, only 39 (10.8%) LC-IIP patients received anti-ILD treatment. There were more LC-ILD patients in the 2018–2021 group than in the 2014–2017 group (5.16% vs. 2.03%, p < 0.001). The underlying causes of ILD were significantly different between the 2018–2021 group and the 2014–2017 group (p < 0.001). After adjusting for the number of hospitalized patients having the same LC pathological pattern, SCLC was determined to be the most likely to be concomitant with ILD, followed by SCC. Most LC-ILD patients were scheduled for anti-LC therapy; however, treatments for concomitant IIP were usually ignored. LC treatment-associated ILD should receive more attention than before. |
format | Online Article Text |
id | pubmed-9885922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98859222023-01-30 Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment Chen, Ruxuan Shao, Chi Liu, Xiangning Huang, Hui Pan, Boju Xu, Kai Zhu, Rui Li, Mei Zhao, Yang Chen, Keqi Wang, Mengzhao Xu, Zuojun Clin Exp Med Research This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective analysis of the clinical characteristics of hospitalized LC patients with definite pathological diagnoses was performed from 2014 to 2021. ILD was defined after the review of chest CT imaging. There were 13,085 hospitalized LC patients. Among them, 509 patients (3.89%) had 551 cases of ILD. There were variable underlying causes of ILD, including idiopathic interstitial pneumonia (360 patients), LC treatment-associated ILD (134 cases), and connective tissue disease-associated ILD (55 patients). Although most LC-ILD patients were suffering from adenocarcinoma (204/40.1%), SCLC patients were prone to concomitant ILD (10.8% of all SCLC cases), followed by SCC (9.6% of all SCC cases). All but 10 LC-ILD patients received anti-LC treatment; however, only 39 (10.8%) LC-IIP patients received anti-ILD treatment. There were more LC-ILD patients in the 2018–2021 group than in the 2014–2017 group (5.16% vs. 2.03%, p < 0.001). The underlying causes of ILD were significantly different between the 2018–2021 group and the 2014–2017 group (p < 0.001). After adjusting for the number of hospitalized patients having the same LC pathological pattern, SCLC was determined to be the most likely to be concomitant with ILD, followed by SCC. Most LC-ILD patients were scheduled for anti-LC therapy; however, treatments for concomitant IIP were usually ignored. LC treatment-associated ILD should receive more attention than before. Springer International Publishing 2023-01-30 2023 /pmc/articles/PMC9885922/ /pubmed/36715832 http://dx.doi.org/10.1007/s10238-023-00999-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Chen, Ruxuan Shao, Chi Liu, Xiangning Huang, Hui Pan, Boju Xu, Kai Zhu, Rui Li, Mei Zhao, Yang Chen, Keqi Wang, Mengzhao Xu, Zuojun Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment |
title | Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment |
title_full | Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment |
title_fullStr | Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment |
title_full_unstemmed | Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment |
title_short | Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment |
title_sort | clinical spectrum of chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of lc treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885922/ https://www.ncbi.nlm.nih.gov/pubmed/36715832 http://dx.doi.org/10.1007/s10238-023-00999-1 |
work_keys_str_mv | AT chenruxuan clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT shaochi clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT liuxiangning clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT huanghui clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT panboju clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT xukai clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT zhurui clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT limei clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT zhaoyang clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT chenkeqi clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT wangmengzhao clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment AT xuzuojun clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment |